期刊
NATURE REVIEWS NEUROLOGY
卷 11, 期 8, 页码 429-+出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrneurol.2015.127
关键词
-
Bevacizumab is approved for use in recurrent glioblastoma, but whether it benefits patients with newly diagnosed glioblastoma remains unclear. Two new studies further question the use of the bevacizumab in this context, but leave much to be clarified about its optimal clinical application.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据